GYRO.NASDAQGyrodyne, LLC

8-K: Gyrodyne LLC Faces Uncertainty in Asset Sales and Liquidation

Sentiment:

Current Report (Form 8-K)


Gyrodyne LLC's CEO outlines challenges in property sales, potential value reduction in a state sale versus a prior developer agreement, and ongoing legal proceedings impacting liquidation timelines.

Delay expectedProgress toward the conditions to closing under the B2K agreement has slowed significantly due to an unresolved dispute over a visual easement.The company now believes the B2K transaction could extend well beyond 2028, if it occurs at all.The company is pursuing a termination of the B2K agreement contingent on a sale to New York State, which it anticipates could close in the second half of 2027, indicating a shift in expected timelines.The Article 78 proceeding appeal is ongoing, and a hearing date is still pending.
Worse than expectedThe preliminary estimate of net assets in liquidation per share has decreased significantly from $12.30 as of June 30, 2026, to $10.75 as of September 30, 2026.This decrease is attributed to a lower estimated value from a potential sale to New York State compared to the prior B2K transaction, including estimated termination costs.The B2K transaction faces significant risks of not closing, impacting the projected liquidation value.Interest rates on extended loans have substantially increased, impacting financing costs.

Summary

  • Gyrodyne LLC's CEO, Gary Fitlin, presented remarks at the 2026 Annual Shareholders Meeting, detailing the company's progress and challenges in its liquidation process.
  • The company has restructured operations, reducing its employee headcount to one (the CEO) to save approximately $620,000 over the remaining liquidation period.
  • Loan extensions were secured for the Cortlandt Manor medical office property and a term loan, with new interest rates significantly higher than previous ones.
  • The company is defending an appeal in an Article 78 proceeding related to Flowerfield subdivision approvals.
  • Costs in excess of operating receipts for the first six months of 2026 were approximately $677,000, a slight decrease from the prior year.
  • Occupancy rate was 80% as of June 30, 2026, down from 82% at the end of 2025.
  • The estimated net assets in liquidation per share decreased to approximately $10.75 as of September 30, 2026, from $12.30 as of June 30, 2026.
  • This decrease is primarily due to a lower estimated value from a potential sale to New York State compared to a prior agreement with B2K Smithtown LLC, including estimated termination costs.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant uncertainties and potential value reduction in asset sales, despite management's efforts to mitigate risks.

Positives

  • Successful restructuring of operations, reducing employee headcount to one (CEO) to achieve significant cost savings of approximately $620,000.
  • Secured extensions on key loans for the Cortlandt Manor property and a term loan, with rates believed to be below alternative financing options.
  • Costs in excess of operating receipts decreased slightly in the first six months of 2026 compared to the same period in 2025.
  • New leases and favorable expense variances contributed to a $0.54 per share increase in estimated net assets during the first half of 2026.
  • Management believes a potential sale to New York State, despite a lower gross price, offers a higher risk-adjusted value and a shorter completion time compared to the B2K transaction.

Negatives

  • Economic headwinds including persistent inflation, elevated interest rates, and downward pressure on occupancy and rents continue to challenge real estate companies like Gyrodyne.
  • The occupancy rate decreased to 80% as of June 30, 2026, from 82% at the end of 2025.
  • The loan secured by the Cortlandt Manor property now bears interest at a fixed rate of 7.28%, substantially higher than the prior rate of 3.75%.
  • The $1.5 million term loan extended has an interest rate of 15%.
  • Significant decrease in the preliminary estimate of net assets in liquidation to approximately $10.75 per share as of September 30, 2026, down from $12.30 per share as of June 30, 2026.
  • The B2K transaction for undeveloped Flowerfield acreage faces significant risk of not closing by the end of 2028, or at all, due to an unresolved issue with an adjoining property owner.
  • A potential sale to New York State would necessitate a significant payment to B2K to terminate their agreement.
  • The company continues to target completion of liquidation by December 31, 2028, but this timeline is subject to considerable uncertainty.

Risks

  • The success of the B2K transaction is heavily contingent on securing entitlements, which has slowed significantly due to an unresolved dispute over a visual easement.
  • There is a material risk that the B2K transaction will not close by the end of 2028, if at all.
  • The outcome and timing of the Article 78 proceeding appeal related to Flowerfield subdivision approvals are uncertain.
  • The company is negotiating a termination of the B2K agreement contingent on a sale to New York State, which may require a significant payment to B2K.
  • There is no assurance that agreements with New York State or B2K will be signed, or that a sale to the State will close.
  • The marketing campaign for Cortlandt Manor indicates that current market demand for medical office development may not support the permitted square footage.
  • The ultimate value realized from real estate sales is largely dependent on economic conditions, inflation, interest rates, and the speed of governmental and judicial actions.
  • The company remains open to offers for properties as-is or for the sale of the company itself, indicating potential distress or a need for alternative solutions.

Future Outlook

The company continues to target completion of its liquidation by December 31, 2028. However, the timeline is subject to significant uncertainties related to property sales, legal proceedings, and municipal approvals. A potential sale to New York State is being pursued as a potentially faster and less risky alternative to the B2K transaction, with an estimated closing in the second half of 2027, contingent on negotiations.

Management Comments

  • We undertake no obligation to update these statements.
  • I sincerely want to thank our team of directors and advisors for their relentless focus on the mission of maximizing future distributions to our shareholders, including the substantial portion of their director and advisory fees that they have deferred.
  • I would also like to thank Peter Pitsiokos for his loyalty and contributions over his 34-year tenure. He will surely be missed.
  • While this is substantially higher than the prior rate of 3.75%, we believe the new rate is materially below the alternative financing options available to us.
  • We remain confident in our position, although there can be no assurance as to the outcome or timing of the appeal.
  • The success of this transaction and our overall efforts to sell our properties is heavily contingent on securing entitlements.
  • Unless that issue is resolved, we believe there is a material risk that the B2K transaction will not close by the end of 2028, if at all.
  • Subject to those agreements, the Company believes that a sale to the State, net of termination costs and although at a lower gross price, would result in a higher risk-adjusted value for shareholders and could be completed in a shorter period of time.
  • While the decrease is significant, we believe it is substantially less, on a risk-adjusted basis, than the additional costs, delay and uncertainty associated with continuing to pursue the B2K transaction.

Industry Context

StockSavvy.ai notes that Gyrodyne's challenges reflect broader economic headwinds impacting the real estate sector, including persistent inflation and high interest rates, which have made it difficult for companies to maintain occupancy, increase rents, and execute property sales, particularly for companies in liquidation phases.

Legal Proceedings

  • The company continues to defend the Flowerfield subdivision approvals in the petitioners' appeal of the dismissal of the Article 78 proceeding. Briefing was completed in July 2025, and the company awaits a hearing date. Management remains confident in their position, but the outcome and timing are uncertain.

Stakeholder Impact

  • Shareholders: Potential reduction in net asset value per share due to revised sale estimates and termination costs. The company is pursuing a strategy believed to offer higher risk-adjusted value, but this involves uncertainty and potential delays.
  • Employees: Significant reduction in workforce to one employee (CEO) to reduce costs.
  • Advisors/Directors: A substantial portion of their fees have been deferred, indicating a commitment to maximizing shareholder distributions.
  • B2K Smithtown LLC: The outcome of negotiations for termination of their agreement is uncertain and may involve a significant payment.
  • New York State: Potential buyer of undeveloped Flowerfield acreage, which could simplify development conditions and infrastructure requirements.

Next Steps

  • Continue to defend the Flowerfield subdivision approvals in the Article 78 proceeding appeal.
  • Negotiate and potentially close a sale of undeveloped Flowerfield acreage to New York State.
  • Negotiate an agreement with B2K to terminate their agreement, contingent on a sale to the State.
  • Continue marketing Cortlandt Manor with the goal of entering into sales agreements at post-entitlement values.
  • Work with JLL and the Town of Cortlandt on an alternative mixed-use development and marketing strategy for Cortlandt Manor.
  • File the third quarter 10-Q, which will include an updated preliminary estimate of net assets in liquidation.
  • Continue efforts to maximize future distributions to shareholders.

Key Dates

DateDescription
2025-12-31Maturity date of the $1.5 million term loan, which was extended for an additional 24 months commencing January 1, 2026.
2026-06-30Date as of which estimated liquidating distributions were $12.30 per share.
2026-07Briefing on the appeal of the Article 78 proceeding was completed.
2026-10-02Date as of which employee headcount was reduced to one full-time employee (CEO).
2026-10-10Initial maturity date of the loan secured by the Cortlandt Manor medical office property, which was extended for an additional five years.
2026-11-05Date of the 2026 Annual Shareholders Meeting where CEO Gary Fitlin presented remarks.
2026-12-31Targeted completion date for the liquidation of Gyrodyne LLC.
2027-12-31Previously anticipated closing date for the B2K transaction.

Recommendation

hold

The filing indicates significant headwinds and uncertainties regarding the company's liquidation process and asset sales, leading to a reduced estimate of net assets in liquidation. While management is taking steps to mitigate risks and explore alternatives, the substantial delays, legal challenges, and negotiation complexities suggest a cautious approach. The potential for a lower realized value and extended liquidation timeline warrants a hold recommendation until greater clarity emerges on the sale to New York State or other resolutions.

Keywords

liquidation distributions, asset sale, real estate, Flowerfield, Cortlandt Manor, Article 78 proceeding, entitlements, shareholders meeting

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.